Here are four things to know.
- Dr. Gottlieb said President Trump’s federal hiring freeze no longer applies to the FDA.
- The FDA head responded to criticism surrounding the proposed budget, saying he was not involved with developing the budget proposal, according to the report.
- Dr. Gottlieb said he will soon share a “drug competition action plan” and a list of off-patent drugs with no current generic competition.
- He also said the FDA plans to update its risk evaluation and mitigation strategy regulations — which ensure the benefits of a drug or biologic outweigh its risks — to prevent drugmakers from taking advantage of the rules for their own benefit, reports Regulatory Focus.
More articles on supply chain:
Supply chain tip of the day: Schedule daily huddles with surgical teams
Controversial bill addressing diabetes drug prices reaches Nevada governor’s desk: 5 things to know
Marijuana-derived epilepsy drug nears FDA approval
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
